Stoke Therapeutics, INC Schedule 13G passive stakes

The Toronto-Dominion Bank and TD Securities Inc. have updated their beneficial ownership filing for Stoke Therapeutics, Inc., reporting a combined 4.9% stake.

FMR LLC, through its affiliates, has reported a beneficial ownership of 8.5% of Stoke Therapeutics Inc.'s common stock as of June 30, 2026.

Lynx1 Capital Management LP has reported an 8.1% beneficial ownership stake in Stoke Therapeutics, Inc. as of March 31, 2026.

Redmile Group, LLC and Jeremy C. Green have filed an amendment to their Schedule 13G, reporting a 6.7% beneficial ownership stake in Stoke Therapeutics, Inc.

The Toronto-Dominion Bank and its subsidiary TD Securities Inc. have reported beneficial ownership of 5.4% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 9.9% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 5.2% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a 9.8% beneficial ownership stake in Stoke Therapeutics Inc. as of December 31, 2025.

Cowen Financial Products LLC has reported a complete divestment of its beneficial ownership in Stoke Therapeutics Inc common stock, transferring it to an affiliated entity, The Toronto Dominion Bank.

The Toronto-Dominion Bank has reported a 5.8% beneficial ownership stake in Stoke Therapeutics, Inc., holding 3,173,258 shares of common stock.

FMR LLC and Abigail P. Johnson have reported a 12.5% beneficial ownership stake in Stoke Therapeutics Inc., as detailed in their latest Schedule 13G amendment.

BlackRock, Inc. has reported an increased beneficial ownership of 6.8% in Stoke Therapeutics, Inc. common stock as of September 30, 2025.

Redmile Group, LLC and its principal Jeremy C. Green have reported an 8.0% beneficial ownership stake in Stoke Therapeutics, Inc.

FMR LLC and Abigail P. Johnson report a 13.6% beneficial ownership stake in Stoke Therapeutics Inc., signaling a significant institutional investment.

Cowen Financial Products LLC has reported a 5.8% beneficial ownership stake in Stoke Therapeutics Inc., holding over 3.17 million shares of common stock.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.7% of Stoke Therapeutics, Inc.'s common stock as of June 30, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a beneficial ownership of 10.7% of Stoke Therapeutics Inc.'s common stock as of May 30, 2025, held in the ordinary course of business.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive beneficial ownership stake in Stoke Therapeutics, Inc. as of March 31, 2025.

BlackRock Portfolio Management LLC has filed a Schedule 13G, revealing a 5.1% beneficial ownership stake in Stoke Therapeutics, Inc. as of March 31, 2025.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 9.99% in Stoke Therapeutics, Inc., totaling 5,310,033 shares as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.5% of Stoke Therapeutics, Inc.'s common stock as of December 31, 2024.